This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good morning and welcome to the MARPAY first quarter 2022 financial results conference call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Marpe's CFO, Yoram Bebring.
spk00: Please go ahead. Thanks, operator.
spk03: Welcome, everyone, to our first quarter 2022 call. With me on the call today are Marpe's Chief Executive Officer, Emundo Gonzalez, and Chief Financial Officer, Yoram Bebring. Before turning the call over to Emundo, please note that we'll be discussing certain non-GAAP financial measures that we believe are important when evaluating MARPE's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and the reconciliations thereof can be found on the press release that is posted on our website. Also, please note that certain statements made during this call will be forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results for Marpe to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available at MarpeHealth.com. And with that, I will turn the call over to Marpe's CEO, Emundo Gonzalez. Emundo?
spk04: Thank you, Simon. Good morning, everyone, and thank you for joining us. It's a pleasure to be here to review our Q1 2022 results. Let me spend a minute summarizing our strategy as I know this is the first call for some of you. Marpeza Technology Company, we are using the power of technology to fundamentally change the health plan offered by employers to their employees. Our clients are self-insured employers across the country. These are the companies and local government agencies that have chosen not to buy traditional health insurance for their employees, but rather to self-insure their health care expenses. We manage all the health care plans on their behalf. Our mission is to help these self-insured employers get value out of their health care dollars and, of course, get control over these ever-rising costs. We focus on members, the employees of our clients, and on getting them the best care possible as early as possible. We do this by predicting costly events before they happen, and we then reach out to members to get them the very best care. On our last call, I shared with you that we had recently hired Lutz Finger, who was leading a large product group at Google. Lutz is our president in charge of product and technology. I'm glad to report that LUTs is proving not only to be the force of five people, but also is setting up a product strategy for the next few years. This strategy centers on the member and making sure that our tech is pushing forward our mission in two critical ways. First, we want to make sure we can identify what works empirically for our member's benefit. we want to further understand our members so we can best match them to quality care early. I would remind you that the majority of a healthcare plan's costs are often driven by less than 20% of members. We strive to know not only who these members are, but who they will be in the future, and to understand what programs best work for those willing to engage. This is why we chose to become a healthcare payer. We believe we are uniquely positioned to drive change in controlling costs while providing access to high quality healthcare, which improves lives. In addition to products that Lutz and his team are designing for the future, I'm glad to report that we will soon be launching MarpayRx. This is our pharmacy benefit manager, which shall be powered by a leader in the space. Our goal here is to bring additional value to our members and to our employer groups. What does this mean from our pay? It means that we can expand our share of wallet by also providing the drug benefit to our employer groups. This not only means additional fees, which are per employee per month, like our core admin fees, but it also opens the opportunity to share the savings that we bring. Roughly speaking, Drugs account for approximately 20% of healthcare spending. Often, there is no transparency on the real cost of drugs due to rebates from big pharma. We strive to be fully transparent in terms of showing our employer groups the rebates and sharing some of them, in some cases all of them, with them. We also see tremendous opportunities to bring more access to high quality treatments to our members by a patient assistance programs and importation programs, which can dramatically lower the cost of drugs for members who share in these costs. And of course, for our clients, the self-insured employers. Lastly, and perhaps most importantly, there are many insights that can be mined in drug data, which we intend to use for the benefit of our members. We continue our journey of transforming how a healthcare payer does the basics, that is, reviewing, adjudicating, and paying medical claims. I shared with you in the past that during the last quarters of 2021, we were able to cut our own cost of administering a claim by more than half. This is what tech looks like when deployed correctly. We're continuing on this path, and my aim continues to be significantly beating the industry's average cost. Moving on to sales and marketing. We have invested time and money in this last year in building relationships with the largest healthcare brokers in America. We strive to be in the flow in terms of receiving RFPs and other requests for proposals. I will share with you that our RFP level is now approximately two-thirds of what we did in all of 2021. I will remind you that self-insured groups tend to switch plans on September 1st, October 1st, and January 1st, with January 1st being the biggest date for commercial plans. The sales cycle begins in earnest in July and extends into the fall. Our second annual broker retreat next month will bring together top producers and senior executives from the largest healthcare brokers in America. We believe the investments we've made and continue to make have set us up for productive and hopefully very, very fruitful 2022 selling season. Moving on to the quarter and the latest developments, I will let Yoram provide you with the details, but in Q1, we grew 5.5% versus Q4 of 2021. Our revenue reached $6.2 million in Q1 of 2022. During the first quarter, the number of our customers' employees covered under the company's administered health plans decreased to 21,139 versus 25,136 at the end of 2021. This net reduction in employee lives is in large part due to the loss of one large customer, which we will name Customer B. As a client, Customer B as a client, as well as several, and legacy Continental Benefits clients. In the case of customer B, despite the fact that they were a very happy customer, our network partner priced their claims higher than an alternative network we do not work with. The increase in revenue in Q1, despite this loss, is largely driven by payments related to run out for departing clients. We are working hard to make sure as well as that we are serving clients and that they are very highly satisfied. We have ramped and revamped the entire account management function under new leadership. We believe the best way to ensure that churn is low is to continue executing on our mission. At the end of the day, healthier groups cost less. That's what we're striving for. Now let me turn it over to Yoram, who will go through the Q1 financial results. Yoram?
spk01: Thank you, Edmondo, and good morning, everyone. First, I want to remind us all that prior to April 1st, 2021, when we acquired Continental Benefits, MARPA did not have any revenues, which is the reason that our comparative revenue number for the first quarter of 2021 is zero. Our revenues for the first quarter of 2022 were approximately 6.2 million, compared to approximately 5.9 million in the fourth quarter of 2021, and revenues of 4.8 million for the third quarter of 2021. As Edmondo said, we're guiding our revenues to declining in the second quarter of 2022. Edmondo explained that our business is a lumpy business. Our customers typically sign annual agreements with fixed fees based on their number of employees. As long as the number of employees remains stable during the year, which is usually, though not always the case, the monthly revenues we derive from this customer also remains stable. When the contract year ends, our customers will typically rely on brokers to assist them to make the selection of their TPA or health insurance vendor, have a decision to make. Will they stay with the current TPA or insurance company, seek a new vendor, or simply price check the market to ensure that they are paying reasonable fees to their current TPA or insurance company? Because of the ongoing increase in the cost of healthcare, most companies see increased healthcare insurance costs for the fully funded plans or increase in the cost of claims of their employees for self-insured plans like the ones we manage. This inflationary environment tends to promote companies to seek alternatives as they try to keep their costs in check. The brokers also have an inherent interest to show their customers that they are getting the best possible deal, which usually means seeking bids from multiple vendors, which in our case means multiple TPAs assuming they want to self-insure. Sometimes excellent TPAs can lose a customer only because that customer had a high claims year and the low-quality TPA is prepared to low-ball their fees. And sometimes, like what happened in the customer B situation, a network provider that is prepared to discount their fees to win a customer B as a customer. For the customer, customer meaning employer, the decision who to choose as their TPA or health insurance provider is a complex one. And the influence of the broker on this decision can make it even less straightforward. All these elements can promote changing of vendors for short-term savings, which may or may not be the right decision from a longer-term perspective. Another element in this revenue lumpiness is that annual contracts tend not to be evenly spread throughout the year. More than 60% of the companies renew change plans on January 1st, and other key dates are October 1st and September 1st, and to a much lesser extent, July 1st. This means that a lot of our marketing efforts will only bear fruit towards the end of the year. We believe that in the long term, our strategy to provide excellent service with advanced technology-driven value-added services at competitive prices will help us grow by winning new business and reducing churn. But we're not insulated from the market dynamics, including the bumpiness like the one we just experienced with Customer B. This is just part of the courses we grow into a successful, profitable TPO in the future. Moving on to expenses, I will be comparing the first quarter of 2022 expenses to the fourth quarter of 21 expenses. We're ignoring first quarter 21 expenses as they do not include the continental benefit expenses and are therefore not comparable to our Q1 22 expenses. Cost of revenues include our cost of processing and adjudicating claims, our customer service costs, and the amount charged by third-party vendors for their services that we resell to our customers. Our cost of revenue for Q1 excluding depreciation and mortization were approximately 4.5 million or 73% of revenues, compared to 72% of revenues for the fourth quarter of 2021. This decline reflects the impact of new customers and customers that churned on our gross profit. Gross profit not including the impact of depreciation and amortization was approximately $1.7 million unchanged from the fourth quarter. Our first quarter operating expenses, not including cost of revenues, depreciation and amortization, and stock-based compensation decreased by approximately $700,000 compared to the fourth quarter. Approximately $400,000 of the decrease was due to decreased sales and marketing expenses, and approximately $300,000 of the decrease was due to various one-time costs and accruals that we incurred in the fourth quarter, which was our first quarter as a public company. Operating loss for the first quarter was $5.5 million compared to $5.7 million for the fourth quarter. A net loss for the first quarter was approximately $5.5 million, or $0.28 per share, compared to a net loss of $5.7 million, or $0.34 per share, for the fourth quarter. Excluding stock-based compensation of $666,000 and depreciation and amortization expenses of $826,000, adjusted EBITDA for the first quarter was a negative of approximately $4 million, compared to a negative of $4.7 million in the fourth quarter of 2021. Moving on to our 2022 revenue guidance, we expect second quarter 2022 revenues to be in the range of $5.2 to $5.5 million. And with that, we will open the call for questions. Operator?
spk02: Thank you. We will now begin the question and answer session. To ask a question, you may press star then 1 on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you'd like to withdraw your question, please press star then 2.
spk00: At this time, we will pause momentarily to assemble our roster. Again, if you have a question, please press star then 1. As there are no questions, this concludes our question and answer session.
spk02: I would like to turn the conference back to Edmundo Gonzalez for any closing remarks.
spk05: Thank you very much, everyone, for joining. We appreciate your support and your interest. And have a good day. Thank you so much.
spk02: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer